Biologics in Allergy and Asthma Treatment—Clinical Updates and Perspectives

Dear Colleagues,

Over recent years, we have witnessed unprecedented progress in the management of asthma and allergic diseases. This progress has largely been due to the introduction of biological treatment. Monoclonal antibodies are gradually becoming the mainstay of management of severe asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and atopic dermatitis. We can also see growing evidence of the efficacy and utility of biologics in chronic obstructive pulmonary disease (COPD) and hereditary angioedema (HAE), while new evidence is emerging regarding the possible use of biologics in eosinophilic esophagitis and food allergy.

In addition to data from clinical trials, evidence from real-world studies confirms the benefits of biological treatment for patients with allergic and asthmatic conditions.

It is, therefore, my pleasure to invite you to share your experience and views on this topic. Biologics, a young and prolific Scopus-indexed journal dedicated especially to the dissemination of current achievements in the field of, among others, biological treatment, has launched this Special Issue, which, I hope, you will find a perfect platform for your submissions.

Types of submissions that you are invited to share include primarily, but not exclusively, the following:

• Results of prospective and retrospective real-world studies investigating efficacy of biologics in allergy, asthma and conditions that are also managed by allergists (e.g., urticaria, HAE);
• Case-series and case reports accompanied by a literature review, presenting the use of biologics in allergic conditions that are non-standard or off-label indications, and provide inspiration and perspective for future fields of implementation of biologics;
• Narrative and scoping reviews presenting current knowledge, future perspectives and/or research gaps in the field of biological treatment of allergy and asthma;
• Systematic reviews and meta-analyses of studies assessing biologics’ efficacy in allergy and asthma management.

We hope you find this initiative interesting and that you will consider this Special Issue of the Biologics journal for your next submissions.

Dr. Marcin Kurowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• allergy
• asthma
• urticaria
• hereditary angioedema (HAE)
• atopic dermatitis
• chronic rhinosinusitis with nasal polyps
• chronic obstructive pulmonary disease (COPD)
• type 2 inflammation
• biological treatment
• clinical efficacy
• real-world evidence